PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - What are the Different Ways Securities Can Be Offered and Sold? (Part 2)
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - What are the Different Ways Securities Can Be Offered and Sold? (Part 1)
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - What is a Public Offering?
AGG Talks: Cross-Border Business Podcast - Episode 25: Venture Capital Trends and Fundraising Strategies for Foreign Startups Expanding to the U.S.
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - Rule 506 Offerings
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - What is a Private Offering?
What's Shaping the Capital Raising Environment?
Investment Opportunities in Italy's Tech Market
Raising a Down Round and How to Be Prepared
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - What Laws Affect Securities Offerings?
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - What Makes it a Securities Offering?
JONES DAY TALKS®: A Trip to the Dark Side – Venture Capital Down Rounds and Recaps
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - Why Raise Capital?
The Power of Genuine Networking for Entrepreneurs With OneSixOne Ventures with Pablo Casilimas and Justis Mendez
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - The Aspects of Raising Capital from Start-Ups to More Established Companies
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 182: Life Sciences Startups and Leadership with Scott Pancoast of Zylo Therapeutics
Through the Lens: From serial entrepreneur to neutral who gets deals done - Focus on Daniel Garrie
Point by Point: The Sale of Dental Practices, Raising Capital and More with Logan Growth Advisors
Disrupting Systemic Economic Injustice in the Startup Ecosystem, with Resilient Ventures' Tom Droege and Keith Daniel
From Accidental Entrepreneur to a $2.5M raise, with Cycle Labs' Josh Owen
Cooley handled 238 reported venture capital financings in Q2 2025, representing $6.5 billion of invested capital. Deal count increased by more than 20% across all stages of financing compared to the previous quarter, with...more
This is an excerpt from Securities Class Action Filings 2024 Midyear Assessment - COVID-19-related filings are on pace to increase by 27% in 2024. The number of cryptocurrency-related filings in 2024 H1 (three) was in line...more
In recent weeks, Arm, Instacart, and Klaviyo priced their IPOs, marking some of the first notable IPOs by technology companies in the past 18 months. As macroeconomic conditions and market sentiment appear to stabilize,...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2023 include: • Life sciences VC deal value totaled $5.0 billion across 364 deals, representing a 40.9% decline in value...more
During this session, Partner Luc Jansen moderated a panel that provided an overview of the current fundraising market and offered insights into which strategies are yielding successful outcomes....more
Our survey analyzed the terms of 287 venture financings closed in the fourth quarter of 2021 by companies headquartered in Silicon Valley. Key Findings - • Valuation results again reached new record highs, with the...more
The Israeli M&A market has enjoyed a spectacular H1 2021. In just the first six months, deal value in the country has reached US$28.7 billion, already higher than any annual total on Mergermarket record (since 2006)....more
In April 2018, the Hong Kong Stock Exchange’s (HKEx) rule amendments permitting the listing of innovative, high-growth companies with dual-class share structures and pre-revenue biotech companies went into effect. The...more
The 2015 IPO market produced 152 IPOs, a disappointing tally that lagged well behind the 244 IPOs in 2014 despite continued strength in the life sciences sector. Setting aside the anomalous years of 2008 and 2009, however,...more